Five years ago, I finished treatment and was determined to be no evidence of disease. Until my most recent CT scan, there’s been no sign of recurrence.

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...

Dr Kami Maddocks shares highlights from ASH 2025, including how the phase 3 EPCORE FL‑1 trial, adding a bispecific antibody to R2 in second‑line or later follicular lymphoma, showed significantly ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma that affects white blood cells called ...

FDA approved tafasitamab with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, based on clinical trial results. Troy Anderson's experience with Monjuvi showed significant ...

The US Food and Drug Administration has granted accelerated approval to the Bruton's kinase inhibitor zanubrutinib (Brukinsa, BeiGene USA) with obinutuzumab (Gazyva, Roche) for relapsed or refractory ...

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma. The FDA has granted Bristol Myers Squibb’s ...